We observed that in the co-culture model of the normal ovarian cancer cells and T cells, the addition of anti-PD-L1 did not elicit a significant immune response, which differed from that in the paclitaxel-based treatment group. This evidence concerns the gene CD274 and ovarian carcinoma.